surmount tirzepatide trials Clinical of subcutaneous (SURMOUNT-1, -2 and -3 SURMOUNT-2: Tirzepatide achieved up to

The bottom of the black rubber stopper inside the syringe barrel is your measurement line

However, orforglipron only activates GLP-1 receptors

The SURMOUNT-5 trial (published in NEJM, 2025) demonstrated mean weight loss of 20.2% with tirzepatide versus 13.7% with semaglutide over 72 weeks in adults with obesity but without diabetes [10]

Customized Dosing and Medication Selection Everyones body reacts differently to medications, so finding the right fit is essential

At Pine Point Medical , our medically supervised programs focus on personalized care, sustainable habits, and long-term wellness

If you were experiencing GI symptoms that you attributed to the medication itself, you may find that they improve at weekly dosing as drug concentrations settle into the tested therapeutic range